India, July 1 -- image credit- freepik

Akums Drugs & Pharmaceuticals, Delhi-based contract development and manufacturing organisation (CDMO), has announced the launch of its DCGI-approved Pregabalin, Methylcobalamin and Duloxetine (Delayed Release) Capsules, a novel triple-action therapy for the management of diabetic peripheral neuropathic pain associated with Vitamin B12 deficiency.

Neuropathy is emerging as a significant public health concern in India, driven by the growing prevalence of diabetes and nutritional deficiencies. India is home to more than 100 million people living with diabetes, and studies suggest that nearly 25-50% of diabetic patients may develop neuropathy during the course of their disease. Vitamin B12 deficiency, ...